American Healthcare REIT, Inc.
AHR
$55.93
+0.29%
American Healthcare REIT, Inc. is a healthcare-focused real estate investment trust that owns and operates a diversified portfolio of clinical healthcare properties, including medical office buildings, skilled nursing facilities, senior housing, hospitals, and other healthcare-related facilities. The company operates through four reportable segments: integrated senior health campuses, outpatient medical, triple-net leased properties, and SHOP, with the majority of revenue derived from its integrated senior health campuses. As a relatively new public entity, having listed in February 2024, the company is positioning itself as a consolidator in the healthcare real estate space, benefiting from demographic tailwinds and a growing demand for senior housing and outpatient care. The current investor narrative centers on the company's strong operational momentum, highlighted by a 16.4% NOI growth and a 93% surge in shares, which has attracted institutional buying and analyst upgrades, while also raising questions about valuation sustainability and the pace of future growth.…
AHR
American Healthcare REIT, Inc.
$55.93
Related headlines
Investment Opinion: Should I buy AHR Today?
Based on the strong buy consensus and average target price of $63.67, the stock is rated a Buy. The thesis is that the company's accelerating revenue growth and improving profitability will drive earnings higher, justifying the premium valuation. The forward PE of 56.5x implies significant earnings growth, and if the company delivers, the stock could appreciate toward the analyst target.
Sign up to view all
AHR 12-Month Price Forecast
The AI assessment is bullish, driven by the company's strong growth trajectory and positive earnings inflection. However, the high valuation and thin margins warrant caution. The stance would be upgraded if the company demonstrates sustained profitability and margin expansion, or downgraded if growth decelerates or margins deteriorate further. The key is to monitor the next few quarters for evidence of sustainable growth.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on American Healthcare REIT, Inc.'s 12-month outlook, with a consensus price target around $63.67 and implied upside of +13.8% versus the current price.
Average Target
$63.67
0 analysts
Implied Upside
+13.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$55 - $74
Analyst target range
The target price range spans from a low of $55.00 to a high of $74.00, indicating a wide spread of $19.00, which suggests moderate uncertainty about the stock's future performance. The low target of $55.00 is near the current price, implying that even the most bearish analyst sees limited downside, while the high target of $74.00 assumes continued strong growth and potential multiple expansion. Recent institutional ratings show a positive trend, with upgrades from Citigroup (from Neutral to Buy) and reaffirmations of Buy/Overweight ratings from UBS, Barclays, and others, indicating that analysts are becoming more optimistic. The wide range between the low and high targets reflects the inherent uncertainty in the healthcare REIT sector, but the overall bullish consensus and recent upgrades suggest that the risk-reward profile remains favorable.
Bulls vs Bears: AHR Investment Factors
The bull case is supported by accelerating revenue growth, positive earnings inflection, and strong analyst sentiment, while the bear case centers on an elevated valuation and thin profitability. Currently, the evidence slightly favors the bulls, as the company's growth trajectory and analyst upgrades provide momentum. However, the key tension is whether the company can sustain its growth and improve margins to justify its high PE ratio. If revenue growth continues at 20%+ and margins expand, the stock could re-rate higher; if growth slows or margins remain negative, the stock could face significant downside. The next few quarters will be critical in resolving this debate.
Bullish
- Accelerating Revenue Growth: Q1 2026 revenue grew 20.4% YoY to $650.8M, up from 15.4% in Q4 2025 and 9.4% in Q3 2025, demonstrating accelerating demand for healthcare properties and successful execution of growth strategy.
- Strong NOI Growth and Institutional Support: The company posted 16.4% NOI growth, attracting institutional buying and analyst upgrades. Recent upgrades from Citigroup (Neutral to Buy) and reaffirmations from UBS and Barclays reflect growing confidence in the company's momentum.
- Positive Earnings Trajectory: Net income turned positive in Q1 2026 at $23.7M (EPS $0.13) versus a loss of $6.8M in Q1 2025, showing a clear inflection point. The forward PE of 56.5x implies the market expects continued earnings growth.
- Analyst Consensus Strong Buy: With a recommendation mean of 1.4 (Strong Buy) and an average target price of $63.67, analysts see 13.8% upside from the current price of $55.93. The high target of $74 implies 32.3% upside.
Bearish
- Elevated Valuation with High PE: The trailing PE of 112x and forward PE of 56.5x are significantly above the broader market and typical REIT valuations, leaving little room for error. If growth decelerates, the stock could face multiple compression.
- Thin Profitability and Negative Gross Margin: Despite revenue growth, Q1 2026 gross margin was -1.3% (gross profit of -$8.6M), indicating that the cost of revenue exceeds direct revenue. This suggests underlying operational inefficiencies that could pressure future earnings.
- High Short Interest and Volatility: The short ratio of 7.96 indicates elevated short interest, and the stock has experienced a max drawdown of -14.08% over the past year. This suggests that some investors are betting against the stock, and volatility is a concern.
- Dependence on Integrated Senior Health Campuses: The majority of revenue comes from the integrated senior health campuses segment, creating concentration risk. Any regulatory changes or operational issues in this segment could disproportionately impact the company.
AHR Technical Analysis
The stock is in a strong uptrend, with a 1-year price change of +31.66% and a 6-month change of +7.70%. The current price of $55.93 sits near the upper end of its 52-week range, at approximately 95.3% of the range (calculated as (55.93 - 40.0) / (58.7 - 40.0) = 0.953), indicating that the stock is trading near its highs, reflecting robust momentum and investor confidence. This positioning suggests the market is rewarding the company's growth trajectory, though it also implies limited upside from a purely technical perspective unless a breakout above the 52-week high of $58.70 occurs.
Beta
0.77
0.77x market volatility
Max Drawdown
-14.1%
Largest decline past year
52-Week Range
$40-$59
Price range past year
Annual Return
+31.7%
Cumulative gain past year
| Period | AHR Return | S&P 500 |
|---|---|---|
| 1m | -2.0% | +3.6% |
| 3m | +11.4% | +2.7% |
| 6m | +7.7% | +11.4% |
| 1y | +31.7% | +18.7% |
| ytd | +18.4% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AHR Fundamental Analysis
Revenue has been growing steadily, with the most recent quarter (Q1 2026) reporting revenue of $650.8 million, a 20.4% year-over-year increase from $540.6 million in Q1 2025. This growth is accelerating, as the YoY growth rate in Q1 2026 (20.4%) is higher than the 15.4% growth seen in Q4 2025 (from $542.7 million to $604.1 million) and the 9.4% growth in Q3 2025 (from $523.8 million to $572.9 million). The revenue growth is primarily driven by the integrated senior health campuses segment, which accounts for the majority of revenue, as evidenced by the resident fees and services revenue of $609.8 million in the latest quarter. This consistent acceleration indicates strong demand for the company's healthcare properties and successful execution of its growth strategy.
Quarterly Revenue
$650774000.0B
2026-03
Revenue YoY Growth
+20.4%
YoY Comparison
Gross Margin
-1.3%
Latest Quarter
Free Cash Flow
$235490000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AHR Overvalued?
Given that the company is profitable with a trailing twelve-month net income of $23.7 million, the primary valuation metric selected is the price-to-earnings (PE) ratio. The trailing PE is 112.05x, while the forward PE is 56.49x, indicating that the market expects significant earnings growth in the coming year, as the forward PE is roughly half the trailing multiple. This gap implies that the market is pricing in a substantial improvement in profitability, which is consistent with the company's recent revenue acceleration and margin expansion. The PE ratio is elevated compared to the broader market, but for a high-growth REIT, such multiples are not uncommon if the growth trajectory is sustained.
PE
112.0x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 32x~243x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
26.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a high debt-to-equity ratio of 0.51, which is moderate but could increase if the company takes on more debt to fund acquisitions. The current ratio of 0.37 indicates potential liquidity concerns, as current liabilities exceed current assets. Additionally, the company's gross margin is negative (-1.3% in Q1 2026), suggesting that direct costs are not fully covered by revenue, which could lead to continued pressure on profitability. The payout ratio of 234% is unsustainable, meaning the dividend is not covered by earnings, posing a risk to dividend sustainability if earnings do not improve.